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The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often limited by the devel-
opment of acute and/or chronic graft-versus-host disease (GVHD). The lack of effective therapies to treat
steroid-refractory GVHD patients has bolstered clinical evaluation of mesenchymal stromal cell (MSC) therapy
for GVHD. Currently, testing of MSCs for the treatment of GVHD has exclusively used allogeneic MSCs despite
emerging evidence that MSCs lose their immunoprivileged status in vivo. We hypothesized that autologous
MSCs could be a viable alternative MSC source for treating active GVHD. MSCs were isolated and successfully
expanded from the bone marrow of 12 volunteers (ages 2 to 55 years) who had allo-HSCT transplants and
subsequently developed GVHD. MSCs from subjects with GVHD demonstrated an initial lag in growth
compared with healthy control subjects; however, this lag disappeared with continued ex vivo expansion.
Immunophenotype and mesodermal differentiation capacity of MSCs from GVHD patients were indistin-
guishable from that of healthy control MSCs. In vitro immunomodulatory functional analyses also demon-
strated that GVHD MSCs were equivalent to healthy control MSCs with regards to dose dependently
suppressing T cell proliferation and up-regulating indoleamine 2,3-dioxygenase expression when primed
with IFN-g. Single tandem repeat chimerism analyses further demonstrated that MSCs expanded from GVHD
patients were exclusively recipient derived. Based on these data, we conclude that recipient-derived MSCs
from patients with GVHD are analogous to MSCs from healthy volunteers and represent a viable option for
clinical testing as an immunomodulatory option for symptomatic GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an effective treatment for aggressive leukemia and
often represents the only option for cure. Alas, a portion of
allo-HSCT subjects develop graft-versus-host disease (GVHD)
as a serious life-threatening side effect. Attempts to bolster
acute and chronic GVHD therapy with immunosuppressants,edgments on page 939.
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15.01.014monoclonal antibody therapy, and photopheresis have so far
proven ineffective, because of lack of efﬁcacy, increased
incidence of infection, and increased toxicity [1-6]. Under-
standably, novel means to mitigate the effects of GVHD are a
priority.
Mesenchymal stromal cells (MSCs) have been regarded as
a promising cellular therapeutic for the treatment of GVHD
because of their anti-inﬂammatory and tolerogenic proper-
ties [7]. Despite encouraging phase I and phase II trials
involving allogeneic MSCs for GVHD [8-13], clinical efﬁcacy
has not been deﬁnitely demonstrated [14]. One possibility for
the lack of efﬁcacy may hinge on the premise that allogeneic
MSCs are immune privileged and can therefore be adminis-
tered universally to any patient. Our research and that of
others have clearly demonstrated that this “universal donor”
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rejected in vivo through both innate and adaptive immune
responses [15-17]. Thus, allogeneic MSCs may not be well
suited for immune-mediated disorders, like GVHD, which
may require multiple infusions to obtain a durable thera-
peutic response.
Whether recipient-derived MSCs for the treatment of
GVHD could be a viable option is unclear; however, in 1995
Lazarus et al. [18] demonstrated that despite high-dose
chemotherapy and radiation, MSCs could be isolated from
some patients who had undergone HSCT for hematologic
malignancies. Investigators have since shown that MSCs can
be isolated from patients with active acute lymphoblastic
leukemia [19], acute myelogenous leukemia [20], and mul-
tiple myeloma [21]; however, no study has evaluated
whether MSCs can be isolated from subjects with pre-
existing or evolving GVHD. In this study we obtained bone
marrow from allo-HSCT volunteers with active GVHD,
determined feasibility of isolating and expanding their MSCs,
and then ascertained the clinical utility of their MSCs by
comparing immunophenotype, plasticity and immune-
modulating functions to MSCs from healthy volunteers.
METHODS
MSC Isolation and Culture
After institutional review board approval and informed consent, MSCs
were isolated from 10 to 20 mL of bone marrow from the iliac crest of
healthy volunteers and subjects with GVHD. Bone marrow aspirates were
diluted 1:2 with PBS and layered onto a Ficoll density gradient. The cells
were centrifuged at 400 g for 20 minutes with no brake and the mono-
nuclear cells collected, washed, and plated in complete humanMSCmedium
(a-MEM, 10% human platelet lysate [hPL], or 10% FBS, 100 U/mL penicillin/
streptomycin) at 100,000 to 300,000 cell/cm2. Nonadherent hematopoietic
cells were removed by changing the medium after 3 days of culture, and
MSCs were allowed to expand for 7 to 12 days. Thereafter, the cells were
passagedweekly by treatmentwith trypsin/EDTA and reseeded in freshMSC
medium at 1000 cells/cm2.
Characterization of Bone Marrow Aspirates
A 100-mL sample of undiluted marrow was analyzed using a particle
analyzer (BD Coulter, Indianapolis, IN) to generate a WBC differential.
Preparation of Platelet Lysate
Outdated platelet pheresis products were purchased from the American
Red Cross, which meet all American Association of Blood Banks (AABB) and
US Food and Drug Administration regulatory requirements for sterility and
infectious disease screening for transfusion products. To generate pooled
hPL (phPL), we used a freezeethaw procedure to fracture the platelets fol-
lowed by a ﬁbrinogen depletion procedure, previously described [22].
MSC Cell Expansion
MSCs were plated at 1000 cell/cm2 and cultured for 5 to 7 days in either
FBS or phPL media and then counted using a Countess automated cell
counter (Invitrogen, Grand Island, NY). Cell sizes were also determined were
using both the Countess automated cell counter and by ﬂow cytometry
using forward and side scatter measurements.
MSC Differentiation
At passage 3, MSCs from normal and GVHD subjects were seeded at
3000 cells/cm2 for adipocyte and osteoblastic differentiation for 3 weeks.
Adipogeneic media consisted of complete culture medium supplemented
with .5 mM dexamethasone, .5 mM isobutylmethylxanthine, and 50 mM
indomethacin, whereas osteoblastic media consisted of complete culture
medium supplemented with 1 nM dexamethasone, 20 mM b-glycerol
phosphate, and 50 mM L-ascorbic acid-2-phosphate. After 3 weeks of dif-
ferentiation MSCs were washed, ﬁxed with 2% formalin/PBS for 1 hour, and
then stained with either Alzarin Red to show osteoblastic differentiation or
Oil Red to show adipogenic differentiation.
Immunophenotyping MSC by Flow Cytometry
MSCs were cultured for 7 days in phPL media, harvested and resus-
pended at a concentration of 1  106 cells/mL, and analyzed by ﬂow
cytometry for the expression of CD45, CD34, CD44, CD73, CD90, CD105, andHLA-I (BD BioSciences). All samples were run on a Canto II ﬂow cytometry
(Beckman Coulter, Indianapolis, IN) with the appropriate isotype control
subjects. Data are presented as mean ﬂuorescent intensity difference
compared with isotype control subjects.
Real-Time Quantitative PCR
MSCs were cultured for a minimum of 7 days and primed for 4 hours
with 10 ng/mL recombinant human IFN-g. DNA-free total RNAwas extracted
and reverse transcribed as described [23]. Real-time quantitative PCR assays
were performed in duplicate on an ABI 7500 Fast Real-Time PCR system
thermal cycler and SYBR Green Mastermix (Applied Biosystems, Grand
Island, NY) with human primer sequences for indoleamine 2,3-dioxygenase
(IDO) and b-actin. Primers were designed using the NCIB/Primer Blast
designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Data
were analyzed using the relative quantiﬁcation method [24].
T Cell Proliferation Assay
Blood was obtained from healthy volunteers after informed consent on
an institutional review boardeapproved protocol. Human peripheral blood
mononuclear cells (PBMCs) were isolated using a Ficoll density gradient.
PBMCs were cultured at 400,000 cells per well in a 24-well plate with or
without MSCs in 10% FBS RPMI. T lymphocytes were stimulated using anti-
CD3/anti-CD28 Dyna beads (Invitrogen). T cell proliferation was determined
4 days later by ﬂow cytometry analysis of Ki67 expression.
Single Tandem Repeat Chimerism Analysis
Single tandem repeat (STR) chimerism testing is used to detect and
quantify donor blood cells present in recipient bone marrow or peripheral
blood post-transplant allo-transplant. At the Emory University Hospital HLA
laboratory, 15 autosomal STR locus-speciﬁc primer sets and the Amelogenin
gender determining marker are used to determine STR chimerism [25]. The
percent engraftment is determined by the area under the curves of peaks
generated from the detectable emission energy of ﬂuorophores (eg, 6-FAM,
VIC, NED, PET, and LIZ) and the number of molecules present.
DNA was extracted from unfractionated whole blood obtained pre-
transplant from each recipient and his or her paired donor. DNA was also
extracted from puriﬁed MSCs isolated from each recipient post-transplant
and cultured in vitro. The extracted DNA was diluted to a ﬁnal concentra-
tion of .125 ng/mL Fifteen autosomal STR markers (including 13 CODIS core
loci, D19S433, and D2S1338) were typed along with Amelogenin using the
AmpFeSTR Identiﬁler Plus kit (Promega Corporation, Madison, WI). PCR
ampliﬁcation was carried out using an MJ research PTC-100 themocycler
(Perkin Elmer, Santa Clara, CA), according to kit protocols. After PCR, 1 mL of
the ampliﬁed products were diluted into 8.7 mL of HieDi formamide
(Applied Biosystems) and .3 mL of LIZ GS500 internal size standard (Applied
Biosystems). Samples were electrokinetically injected at 3 kV for 10 seconds
and separated on a 3130xl Genetic Analyzer (Applied Biosystems) using
POP-4 polymer (Applied Biosystems) on a 36-cm capillary array (Applied
Biosystems). Genotyping was then performed in GeneMapperID v3.2
(Applied Biosystems) using manufacturer provided bins and panels.
Statistical Analysis
Data are reported as mean  SD. All calculations were carried out using
GraphPad Prism software (GraphPad Software, La Jolla, CA). Comparisons
between groups were made by analysis of variance.
RESULTS
Characteristics of Healthy and GVHD Bone Marrow
Between September 2011 and January 2014, we obtained
12 bone marrow aspirates from patients with active acute or
chronic GVHD who were being treated at either the Winship
Cancer Institute, Emory University Hospital, or Children’s
Healthcare of Atlanta’s Aﬂac Cancer and Blood Disorders
Center (Table 1). Compared with marrow obtained from
healthy volunteers, the marrow from GVHD patients had
similar concentrations of leukocytes but had signiﬁcantly
lower platelet counts (Figure 1A) and a signiﬁcantly higher
frequency of monocytes (Figure 1B).
Growth Characteristics of Healthy and GVHD MSCs
We compared the growth kinetics of MSCs derived from
bone marrow MNCs cultured in media supplemented with
either phPL or FBS. Plating bone marrow MNCs in media
supplemented with phPL resulted in more rapid and
Table 1
GVHD Patient Characteristics
Subject Sex Age
(yr)
Malignancy
Diagnosis
Date of
Diagnosis
Date of
Transplant
Type of
Transplant
HLA Match Post-Transplant Prophylaxis
and Treatment
Date of GVHD
Diagnosis
GVHD
Type
Date of Marrow
for MSC Isolation
Days from
GVHD
Diagnosis
to Marrow
GVHD01 Female 55 HLL 1992 5/1/2011 Matched related
donor: PBSC
10 of 10 Tacrolimus, methotrexate,
prednisone
8/15/2011 Chronic overlap 9/20/2011 35
GVHD02 Female 14 Recurrent ALL 8/10/2007 11/22/
2011
Matched related
donor: marrow
8 of 8 Cyclosporine, methotrexate,
topical hydrocortisone
12/21/2011 Acute grade I 1/18/2012 28
GVHD03 Female 9 ALL 5/13/2009 4/23/2012 Partially matched
unrelated: cord
5 of 6 cyclosporine, mycophenolate,
methylprednisolone, ATG,
inﬂiximab, budesonide
5/7/2012 Acute grade III 6/1/2012 25
GVHD04 Female 26 MDS 7/2/2012 10/22/
2012
Matched related
donor: PBSC
10 of 10 Tacrolimus, methotrexate,
prednisone, methylprednisolone,
inﬂiximab, topical triamcinolone
12/14/2012 Acute grade III 2/1/2013 47
GVHD05 Male 50 AML 1/26/2012 9/14/2012 matched unrelated,
donor: PBSC
10 of 10 Tacrolimus, methotrexate,
prednisone
2/28/2013 Chronic overlap 3/14/2013 14
GVHD05 Female 2 JMML 10/18/
2012
1/30/2013 Matched unrelated
donor: marrow
8 of 8 Cyclosporine, methotrexate,
methylprednisolone, orapred
2/18/2013 Acute grade III 3/19/2013 29
GVHD07 Female 29 AML 7/6/2011 3/29/2012 Matched unrelated,
donor: PBSC
10 of 10 Tacrolimus, methotrexate,
prednisone
1/9/2013 Chronic overlap 3/27/2013 77
GVHD08 Female 7 Pre-B ALL 8/23/2012 3/18/2013 Partially matched
unrelated: cord
5 of 6 Cyclosporine, mycophenolate,
methylprednisolone,
budesonide, equine ATG, orapred
4/3/2013 Acute grade III 5/10/2013 37
GVHD09 Female 3 Pre-B ALL 10/12/
2012
3/19/2013 Partially matched
unrelated: cord
5 of 6 Cyclosporine, mycophenolate,
methylprednisolone, equine ATG
4/2/2013 Acute grade IV 5/20/2013 48
GVHD10 Male 7 AML 5/14/2012 8/5/2013 Partially matched
unrelated: cord
4 of 6 Cyclosporine, mycophenolate,
methylprednisolone, prednisone
8/29/2013 Acute grade II 10/2/2013 34
GVHD11 Female 11 Pre-B ALL 3/15/2004 8/19/2013 Matched unrelated
cord
6 of 6 Cyclosporine, mycophenolate,
methylprednisolone, prednisone
9/13/2013 Acute grade II 10/18/2013 35
GVHD12 Male 8 T cell ALL 4/3/2013 12/11/
2013
Partially matched
unrelated: marrow
7 of 8 Cyclosporine, methotrexate,
methylprednisolone, ATG, budesonide
12/26/2013 Acute grade III 2/4/2014 40
HLL indicates Hodgkin’s lymphoma; PBSC, peripheral blood stem cell; ALL, acute lymphocytic leukemia; ATG, antithymocyte globulin; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; JMML, juvenile mye-
lomonocytic leukemia.
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Figure 1. Isolation of MSCs from GVHD patients. (A and B) Comparison of marrow from GVHD and healthy subjects. (C and D) GVHD MSC colonies when expanded in
phPL or FBS. (E) Isolation efﬁciency of MSCs from healthy and GVHD subjects. (F) MSC doubling time at passage 2-4 for healthy and GVHD MSCs. *P < .05, n ¼ 11-12
individual MSC populations.
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supplemented with FBS (Figure 1D). In 4 GVHD MSC iso-
lations the recovery and expansion of MSCs using FBS were
directly compared with recovery and expansion of MSCs
with phPL. MSC expansion occurred in 2 of the 4 GVHD
marrow samples grown in FBS versus all 4 GVHD marrow
samples grown in media supplemented with phPL. For the
remaining 8 GVHDmarrow samples, we solely expanded the
cells in media with phPL and successfully isolated MSCs from
all 8 samples. In the remainder of this work, we only
compared GVHDMSCs and healthy MSCs expanded in media
supplemented with phPL.
In comparing the initial recovery and expansion of MSCs
from the bone marrow MNCs plated, we noted that marrow
from healthy donors behaved in accordance with what we
have seen historically. Typically, recovery of 1 MSC required
plating an average (SD) of 16.68  2.92 MNCs for 9.5  1.98
days (Figure 1E). Conversely, for a similar expansion period
(9.36 1.34 days), the number of GVHDMNCs that needed to
be plated to recover 1 MSCwas approximately 4 times (65.32
 12.36) that of healthy donors (Figure 1E). Despite this
initial lag, once GVHDMSCs began proliferating ex vivo, their
doubling times were similar to that of healthy donor MSCs
(Figure 1F) [22].
Evaluating MSC Source
Although literature reports indicate that most MSCs
derived from allo-HSCT patients are recipient derived [26-28], in several cases a small proportion of MSCs were re-
ported to be of donor origin [29,30]. Because the prevalence
of donor-derived MSCs in GVHD patients has not been
determined, we used STR chimerism testing to determine
the source of our GVHD MSCs. We evaluated 11 of the GVHD
MSC populations we isolated and compared their STR sig-
natures with that of the graft they received and the
recipient’s blood before transplant. In all 11 cases we found
that the MSCs we expanded were exclusively recipient-
derived (data not shown).
Immunophenotype, Differentiation, and
Immunosuppressive Potential of Healthy and GVHD MSCs
As part of International Society for Cell Therapy guidelines
to establish the identity of an MSC population [31], we
cultured cryopreserved low passage (P3-4) MSCs from
healthy and GVHD subjects for 1 week and analyzed their cell
surface expressions of typical markers used to deﬁne MSCs.
In our analysis of MSCs from 12 GVHD patients, we found
that all 12 MSC populations isolated displayed a typical MSC
phenotype with >95% of cells positive for CD44, CD73,
CD105, CD90, and HLA-I and <5% of cells were positive for
CD34, CD45, and CD19. To evaluate differences in the cell
surface expression levels of markers between healthy and
GVHD MSCs, we performed immunophenotyping of 3
healthy and 3 GVHD MSCs populations and calculated the
mean ﬂuorescent intensity for each marker. Despite some
individual variations, there were no signiﬁcant differences in
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markers analyzed between GVHD and healthy MSCs
(Figure 2A). MSCs from 3 healthy donors and 3 GVHD pa-
tients were also cultured for 21 days under osteoblastic and
adipogenic differentiation conditions and showed similar
capacity to differentiated intomesodermal lineages (data not
shown).
Immunomodulatory Effect of Healthy and GVHD MSCs
To evaluate the ability of GVHD MSCs to suppress T cell
proliferation, third-party PBMCs were cultured for 4 days
with either healthy or GVHDMSCs with or without anti-CD3/
CD28 costimulation. In unstimulated PBMCs neither CD4
(7.66%) nor CD8 (6.73%) T cells proliferated appreciably, and
baseline levels of proliferation were not altered by coculture
with MSC. Conversely, stimulation of PBMCs alone with
anti-CD3/CD28 beads caused both CD4 and CD8 T cells to
proliferate extensively (72.5% and 67%, respectively), and
coculture with MSCs could suppress this proliferation
(Figure 2B). Coculturing either GVHD or healthy MSCs at
different ratios with PBMCs (MSC/PBMC 1:5, 1:10, 1:20)
demonstrated that healthy and GVHDMSCs equally and dose
dependently suppressed T cell proliferation in vitro
(Figure 2C). As a ﬁnal measure of the immunomodulatory
action of GVHD MSCs, we compared IDO gene expression
after IFN-g priming. MSCs were plated overnight and stim-
ulated with 10 ng/mL IFN-g for 4 hours or left untreated.Figure 2. Identity and functional analysis of MSCs from GVHD patients. (A) Compariso
(B) Representative ﬂow plots of T cell proliferation assays performed using PBMCs c
activated with anti-CD3/CD28 Dynabeads and cocultured (10:1 ratio) with either healt
CD28 stimulated (Pos) or cocultured for 4 days with varying ratios of MSC:PBMC wit
real-time PCR of healthy or GVHD MSC without or pretreated with 10 ng/mL of recoAfter 4 hours MSCs were washed, lysed, RNA extracted, and
reverse transcribed. The level of IDO expression in untreated
MSCs was negligible, whereas 4-hour IFN-g priming sub-
stantially increased IDO gene expression in both healthy
MSCs and GVHD MSCs (Figure 2D).DISCUSSION
In this study we tested whether MSCs derived from
patients with GVHD are phenotypically and functionally
analogous to MSCs derived from healthy donors. Our data
demonstrate for the ﬁrst time that despite an initial lag in
expansion, clinical grade MSCs with potent immunomodu-
latory activity can be obtained from patients with active
GVHD regardless of age, cancer diagnosis, or donor source.
Consistent with several other studies [26-28], we also
demonstrated that the MSCs derived from GVHD subjects
were exclusively recipient derived.
The initial MSC growth defect we observed in GVHD sam-
ples is consistent with other published reports showing
growth defects in MSCs derived from patients with several
hematological malignancies, including acute lymphoblastic
leukemia [19], acutemyelogenous leukemia [20], andmultiple
myeloma [21] and is consistent with the concept that bone
marrow stromal elements are susceptible to damage by both
radiation and chemotherapy [19,20,32-36]. These studies
would suggest that after bone marrow transplantation then of healthy and GVHD MSCs immunophenotype measured by ﬂow cytometry.
ultured for 4 days unstimulated, activated with anti-CD3/CD28 Dynabeads, or
hy or GVHD MSCs. (C) T cell proliferation suppression index of PBMCs anti-CD3/
h either healthy or GVHD MSCs. (D) Relative IDO gene expression analyzed by
mbinant human IFN-g for 4 hours. n ¼ 3-5 individual MSC populations.
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dispute this premise because we successfully isolated and
expanded MSCs from 3 subjects with acute myelogenous
leukemia and6withacute lymphoblastic leukemia. Inall cases
we found that after the initial lag phase, GVHD MSCs prolif-
erated at similar rates to those of our healthy volunteers. One
possible explanation for this discrepancy could be our utili-
zation of phPL to expand our MSCs as opposed to FBS, which
others have typically used. Along with ourselves, numerous
investigators have shown that phPL is superior to FBS in
expanding MSCs [22,37], and recently we demonstrated that
phPL can rejuvenate presenescent MSCs [38]. Thus, we
postulate that phPL for the ex vivo expansion of GVHD MSCs
can counteract the negative effects conditioning regimes have
onMSCs andmay revitalize GVHDMSCs from a presenescent-
like MSC phenotype as has been described for MSCs from
multiple myeloma patients [21].
Regardless of whether or not MSCs can be isolated from
GVHD subjects, if the resulting MSCs are not functionally
competent, their clinical utility is dubious. Functional ana-
lyses by others suggest that the toxic conditioning used in
allo-HSCT impairs the ability of MSCs to support HSC main-
tenance and growth [20,39-42]; however, whether these
same conditioning regimes compromise the ability ofMSCs to
be immunosuppressive has not been ascertained. Several
studies have shown that MSCs derived from multiple
myeloma patients have impaired immunomodulatory activ-
ity [32,43,44]; however, our data with nonemultiple
myeloma subjects suggests that GVHD MSCs can actively
suppress T cell proliferation and can do so via tryptophan
catabolism through the IDO pathway [45]. From these
observations we conclude that the conditioning regimes and
maintenance regimes used in our GVHD population did not
impact the ability of their MSCs to be immunosuppressive.
Supporting this concept,Wobus et al. [46] exposedMSCs from
healthy donors to lenalidomide and found that lenalidomide
impaired the capacity of MSCs to direct migration of CD34(þ)
HSCs but did not affect their immunomodulatory ability.
Our data support the idea that autologous GVHD MSCs
(like healthy allogeneic MSCs) can induce tolerance by
reducing the expansion of autoreactive T cells and by
inducing regulatory T cells [47,48], but unlike allogeneic
MSCs, autologous GVHD MSCs may also facilitate durable
tolerance by inducing anergy. Anergy induced tolerance in
solid organ transplant is based on the premise that bolus
infusion of donor cells mediates the elimination of donor-
speciﬁc recipient effector T cells but leaves the remainder
of the T cell repertoire intact [49-51]. In contrast to solid
organ transplant rejection, GVHD is driven by donor lym-
phocytes against host antigens, meaning bolus infusion(s) of
recipient cells may help to induce anergy. Supporting this
concept are data from a murine nonmyeloablative allogeneic
bone marrow transplant study that showed that autologous
MSCs infusion enhanced long-term engraftment and toler-
ance [17], whereas infusion of allogeneic MSCs lead graft
failure. Data by Florek et al. [52] also showed that infusion of
apoptotic autologous splenocytes 24 hours before condi-
tioning could delay the onset of GVHD in a murine model.
Whether autologous human MSCs for GVHD can induce
anergy is unproven; however, it does offer an attractive
secondary mechanism by which tolerance may be estab-
lished and can be tested clinically.
Based on these data we conclude that recipient-derived
MSCs from patients with GVHD are analogous to MSCs
from healthy volunteers and represent a viable option forclinical testing as an immunomodulatory option for symp-
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